You are here: Industry Insights > Breast Cancer

News List

Talazoparib Beneficial in Patients With Advanced Breast Cancer drugs
August 16, 2018
Single-agent talazoparib provides significant benefit over standard chemotherapy for patients with advanced breast cancer and germline BRCA1/2 mutation, according to a study published online Aug. 15 in the New England Journal of Medicine.
Breast Cancer Drug Promising in Phase 3 Trial drugs
August 16, 2018
For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests.
Breast cancer device receives FDA approval cphi-online
August 08, 2018
The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.
Mayo Clinic pinpoints genes that raise the risk of triple-negative breast cancer fiercebiotech
August 08, 2018
The ability to identify women who face the highest risk of triple-negative breast cancer could save lives, but only one inherited mutation—in the gene BRCA1—has been definitively linked to this subtype of the disease.....
Kisqali wins speedy US breast cancer nod pharmatimes
July 20, 2018
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
EU reviews first PARP inhibitor for breast cancer pharmatimes
July 18, 2018
MSD and AstraZeneca’s Lynparza will be the first PARP inhibitor to be reviewed in Europe for the treatment of breast cancer, after the European Medicines Agency validated the drug’s marketing application in this setting.
Pfizer files PARP inhibitor for breast cancer in US, EU pharmatimes
July 10, 2018
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
AstraZeneca chalks up double Japanese approval in lung and breast cancer pharmafile
July 06, 2018
First up, Imfinzi (durvalumab) has been authorised as maintenance therapy after definitive chemoradiation therapy (CRT) for the treatment of locally-advanced
Breast cancer is one of the most common cancers in China - and it is on the rise worldpharmanews
July 05, 2018
Among women in China, rates of breast cancer rose around 3.5% each year between 2000 and 2013. In comparison, breast cancer among American women decreased by about 0.4% a year over the same timeframe.
Roche gearing up to file Tecentriq for breast cancer pharmatimes
July 03, 2018
Roche has unveiled data showing that a combination of Tecentriq and Abraxane significantly slashed the risk of disease worsening or death in some breast cancer patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page